Detail akcie Bioton online

Business Summary: Bioton SA is a Poland-based company active in the pharmaceutical sector. The Company is engaged in research, development and wholesale trade of pharmaceutical and biotechnological products. The Company's portfolio consists of oral hypoglycemic drugs (metformin and glimepride) as well as recombinant human insulin in pharmaceutical substance form and for injections. Additionally, the Company provides advertising services. As of December 31, 2011, the Company formed a capital group and operated through its subsidiaries, including BIOTON TRADE Sp. z o.o., Mindar Holdings Ltd, Germonta Holdings Ltd, Tricel SA, SciGen Ltd and BioPartners Holdings AG, among others. On June 12, 2014, it sold a 50% stake in Copernicus Sp. z o.o.
Financial Summary: BRIEF: For the six months ended 30 June 2024, BIOTON SA revenues increased 6% to PLN88.1M. Net loss applicable to common stockholders totaled PLN7.8M vs. income of PLN1.3M. Revenues reflect Insulin (Bioton SA) segment increase of 8% to PLN85.5M, Vietnam segment increase from PLN1.6M to PLN5.4M, China segment increase from PLN0K to PLN2.4M, Philippines segment increase of 78% to PLN2.5M.